EUCTR2020-002249-40-BG进行中（未招募）1 期
Cure COVID: A prospective, controlled, randomized study to compare the efficacy of GNS561 versus standard of care in patients with SARS-CoV-2 (COVID-19) infection.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age 18 or older at the time of enrolment.
- •2. Documented diagnosis of COVID-19 (diagnostic test performed in a certified laboratory) which is preferable. However if limited access to the test, symptoms of COVID-19 associated with lung imaging findings” on chest CT scan: unilateral or bilateral ground-glass opacities and/or consolidation.
- •3. Clinical status: News2 score from 5 to 6.
- •4. Adequate bone marrow and end-organ function defined by the following laboratory results:
- •Bone marrow:
- •- Hemoglobin = 7.0 g/dL,
- •- Absolute Neutrophils Count (ANC) = 1.0 Gi/L,
- •- Platelets = 100 Gi/L;
- •Hepatic function:
- •- Total serum bilirubin = 1.5 x ULN (except patients with Gilbert’s syndrome who must have total serum bilirubin = 3.0 x ULN),
- •- AST and ALT = 5 ULN
- •Renal function:
- •- Serum creatinine = 2.0 x ULN or Cr. Cl. = 30ml/min/1.73m² (MDRD or CKD-EPI formula);
- •5. Willingness and ability to comply with the study requirements;
- •6. Signed and dated informed consent indicating that the patient has been informed of all the aspects of the trial prior to enrolment;
- •7. Women of childbearing potential are required to have a negative serum pregnancy test within 72 hours prior to study treatment start. A positive urine test must be confirmed by a serum pregnancy test;
- •8. Women of childbearing potential and male patients must agree to use adequate highly effective contraception for the duration of study participation and up to 6 months following completion of therapy;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. Patient known to have intolerance or hypersensitivity to chloroquine or any quinoline derivates (quinine, chloroquine, tafenoquine, hydroxychloroquine, mefloquine).
- •2. Patient requires the use of one of the following forbidden treatment during the study treatment period:
- •Major surgery.
- •Live vaccines. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever and BCG. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (Flu-Mist®) are live attenuated vaccines, and are not allowed.
- •3. Any clinically significant cardiovascular condition as judged by the Investigator, like uncontrolled blood pressure, unstable angina, history of myocardial infraction within 6 months, clinically significant peripheral vascular disease
- •4. Known hepatitis B, treated or not, with viral load < 20 UI/mL or Human Immunodeficiency Virus (HIV) infection, with negative viral load and CD4 > 250/mm3, in last 3 months.
- •5. Prior allogeneic bone marrow transplantation or solid organ transplant in the past.
- •6. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
- •7. Pregnant or breastfeeding patient, or expecting to conceive children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of study drugs.
研究者
相似试验
进行中（未招募）
1 期
RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)COVID-19 (infection with SARS-CoV-2 virus)MedDRA version: 21.1Level: PTClassification code 10035737Term: Pneumonia viralSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10061982Term: Severe acute respiratory syndromeSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001113-21-GBniversity of Oxford20,000
进行中（未招募）
Unknown
HS COVID-related post-traumatic stress disorder (PTSD) experimental treatment trialPost-Traumatic Stress Disorder (PTSD)Mental and Behavioural DisordersISRCTN52834682King's College London18
尚未招募
不适用
A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19)COVID-19ITMCTR2000003144Guangzhou Eighth People's Hospital
进行中（未招募）
1 期
Treatments of COVID-19 in primary care in the NetherlandsPatients with symptomatic COVID-19 in the community and in primary care, who are at higher risk of a complicated illness course.MedDRA version: 23.0Level: PTClassification code: 10084268Term: COVID-19 Class: 100000004862CTIS2022-501559-99-00Maastricht University682
进行中（未招募）
1 期
Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.EUCTR2020-001243-15-BEZLeuven200